Table of Contents

Section I: General Information
Chapter 1  What are Combination Products? ................................................................. 1
Chapter 2  Regulatory Strategy .................................................................................. 9

Section II: North America: US and Canada
Chapter 3  US FDA Structure, Office of Combination Products, and Combination Products
  Policy Council ........................................................................................................... 17
Chapter 4  Jurisdiction and Regulatory Pathway .......................................................... 31
Chapter 5  Combination Product Development and Meetings ......................................... 43
Chapter 6  Investigational Use and Human Factors ....................................................... 55
Chapter 7  Current Good Manufacturing Practice (CGMP) ............................................. 67
Chapter 8  Marketing Applications, Premarket Review Pathways, and User Fees ................ 77
Chapter 9  Combination Product Review Process and Labeling ...................................... 93
Chapter 10 Postapproval Modifications ....................................................................... 105
Chapter 11 Postmarket Safety Reporting ...................................................................... 115
Chapter 12 Canadian Combination Products ................................................................ 127

Section III: Europe
Chapter 13 European Union Combination Products .................................................... 143

Acronyms .................................................................................................................. 157
Glossary ..................................................................................................................... 159
Index ......................................................................................................................... 171

Figures
Figure 2-1. Example Regulatory Strategy Document Template ...................................... 14
Figure 3-1. FDA Organization Leadership Chart ......................................................... 19
Figure 3-2. CBER Leadership Chart ......................................................................... 21
Figure 3-3. CDER Leadership Chart ................................................. 23
Figure 3-4. CDRH Leadership Chart .............................................. 26
Figure 4-1. Pre-RFD Process Flow .................................................. 38
Figure 6-1. Interactions of Human Factors and Usability .................... 61
Figure 7-1. Influence of Design Controls on the Design Process ............ 75
Figure 8-1. CTD Triangle .............................................................. 80
Figure 8-2. Inter-Center Consult Request Process Map ......................... 86
Figure 13-1. EMA Organization Chart ............................................. 146

Tables

Table 1-1. Nine Types of Combination Products .......................... 5
Table 2-1. Sample Questions to Inform the Regulatory Strategy ............... 11
Table 2-2. Regulatory Submission Strategy Document Elements ............. 13
Table 2-3. Regulatory Intelligence Resources .................................. 15
Table 3-1. Combination Products Policy Council Membership ............. 28
Table 4-1. RFD and Pre-RFD Comparison ........................................ 36
Table 5-1. Examples of Application-Based Mechanisms for Device-Led Combination Products .............................. 50
Table 5-2. Examples of Application-Based Mechanisms for Drug or Biological Product-Led Combination Products ........................................... 51
Table 5-3. Submission Process for CPAM Requests ........................... 52
Table 7-1. Examples of Design Control Components ............................ 74
Table 8-1. Premarket Regulatory Pathways ................................. 78
Table 8-2. Code of Federal Regulation Link to eCTD .......................... 81
Table 10-1. Type of NDA/BLA Submission for a Change in a Device Constituent Part of a Combination Product Approved Under an NDA/BLA ........................................ 109
Table 10-2. Type of PMA Submission for a Change in a Biological Product/Drug Constituent Part of a Combination Product Approved Under a PMA ........................................ 110
Table 10-3. Postapproval Modifications by Constituent Part .................. 111
Table 11-1. Safety Reporting Requirements—Single Application ........... 118
Table 11-2. Postmarketing Safety Reports—FDA Locations ................ 120
Table 11-3. Timelines for Various Combination Product PMSR Requirements ........................................... 121
Table 13-1. EU Countries and Their Dates of Entry ................................. 144